KEY WORDS OF MODERN ANTIFUNGAL THERAPY

SHORT COURSE ORAL THERAPY

FOR PROLONGED ANTIFUNGAL ACTIVITY



Itraconazole plasma and stratum corneum levels.
Ref.: Fromtling, R.A.: Recent trends in the discovery, development and evaluation of antifungal agents. J.R. Prous Science Publishers (1987)

In the past, fungal infections had to be treated until the lesions had disappeared — and sometimes even longer. Today, with modern oral medication, antifungal therapy may be stopped much earlier.

The explanation is one of pharmacokinetics: because itraconazole is an oral antifungal with a strongly lipophilic profile, it rapidly reaches the lipid-rich tissues, such as those of the skin and the mucosa. From there it is gradually eliminated as the cells desquamate.
Therefore, when treatment is stopped, itraconazole's fungicidal activity continues for up to 4 days in the vaginal tissue and for up to 4 weeks in the skin.

Thus, a conveniently short oral course of itraconazole provides prolonged antifungal activity, allowing treatment to be stopped before the lesions have completely disappeared.

Sporanox*

itraconazole 100 mg

SHORT AND SIMPLE ORAL THERAPY

(See prescribing information below)
Basic dose in dermatology: 1 capsule (100 mg) once daily for 15 days
Standard dose in vaginal candidosis: 2 x 2 capsules (400 mg) for 1 day only

*** Trademarks: SPORANOX, SEMPERA, TRISPORAL**

JANSSEN PHARMACEUTICA
B-2340 Beerse, Belgium
expertise in antimycotic research

Properties: Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, fungal keratitis and oral candidosis. **Dosage and administration:** Vulvovaginal candidosis: 2 capsules (200 mg) morning and evening for 1 day; pityriasis versicolor: 2 capsules (200 mg) once daily for 7 days; tinea corporis, tinea cruris, tinea pedis, tinea manus: 1 capsule (100 mg) daily for 15 days; highly keratinized regions, as in plantar tinea pedis and palmar tinea manus, require 1 capsule (100 mg) daily for 30 days. Oral candidosis: 1 capsule (100 mg) daily for 15 days. Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole) is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanox (itraconazole) has not been associated with hepatic dysfunction, it is advisable not to give this drug to patients with a known history of liver disease. **Nursing mothers:** It is recommended not to breast feed whilst taking Sporanox (itraconazole). **Drug interactions:** Sporanox (itraconazole) should not be given concomitantly with rifampicin.

Full prescribing information is available on request.

INT 91/2255.4/AV9110-4

Christmas cards from the BMA

DESIGN A
BMA Fountain
"Aspiration" by James Wood
Photo by Rosalind Pajak
Actual size 160 mm x 180 mm
45p each, plus postage



DESIGN B
BMA House
by Yvonne Fuller
Actual size 210 mm x 145 mm
30p each, plus postage

DESIGN C
The Council Garden, BMA House
by Tabitha Salmon
Actual size 147 mm x 105 mm
18p each, plus postage

ORDER FORM

BMJ Bookshop (Christmas cards), BMA House, Tavistock Square, London WC1H 9JR

QTY	DESIGN	AMOUNT
	Design A BMA Fountain @ 45p each	
	Design B BMA House @ 30p each	
	Design C The Council Garden @ 18p each	
	Plus postage	
	Total £	

Please add postage
1-10 cards 60p
11-20 cards £1.50
21-30 cards £1.80
31-60 cards £2.75
61-100 cards £4.00

I enclose my cheque for _____ made payable to ***British Medical Journal***

NAME _____

ADDRESS _____

_____

_____ POSTCODE _____

Please print clearly



The future is bright

"Many articles are neither read nor cited; indeed many articles are poor. In general many journals seem to be of little practical help to clinicians facing problems at the bedside."
"... in the course of a year at least half the journals on the shelves are never looked at at all."
"Most editors ... are 'half nun, half whore.'"
"... in the 300 years of their existence journals have done little to examine their own practices."
"What *are* editors?"
"'If an editor does not please himself,' he used to say, 'he will not please anybody.'"
"Defensive editing we do not need."
"Medical journals in developing countries are, with very few exceptions, unattractive."
"I believe that the future for general medical journals—particularly those published in English—is bright. They will undoubtedly change, but they will not disappear."

The debate was lively and the opinions conflicting and forcefully expressed when, to mark its 150 year past, the *BMJ* decided to join with other general medical journals in examining their perhaps not too certain future. At a conference at Leeds Castle editors of major general medical journals throughout the world, with experts in information science, sociology, and epidemiology, discussed the functions and effectiveness of modern journals, and debated possible choices for development. Edited by Stephen Lock, *The Future of Medical Journals* is a unique compilation of papers on this important but little analysed aspect of medical science.

September 1991
UK £14.95; Abroad £17.50 (BMA members £13.95 or £16.50)

Peer review is one of the key processes at several stages of scientific research, applications for a research grant, assessing an abstract of a contribution submitted to a meeting of a scientific society, and refereeing a paper for publication in a journal. Without publication, which entails such preliminary validation (continued afterwards by the journal's general and specialist readers), science cannot advance. And ensuring that peer review is as accurate, fair, and quick as possible is one of the principal tasks of most scientific editors.

Third impression 1991 (with new introduction)
UK £12.95; Abroad £15.50 (BMA members £11.95 or £14.50)



ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE.**

Please send me the following books:

QTY	TITLE	AUTHOR/EDITOR	AMOUNT

Prices include postage, by air abroad

TOTAL £

NAME (print clearly) _____

ADDRESS _____

_____

_____ POSTCODE _____

☐ Please send me a book catalogue

Membership No _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No _____ Exp _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House.



Search 25 Years of the BMJ in Seconds

Save time and money with Maxwell's new BMJ CD-ROM. It gives you thousands of BMJ references, abstracts and articles all on a single disc. It's the most complete, easy-to-use research tool of its kind.

■ **More comprehensive** — 25 years of BMJ MEDLINE references and abstracts plus five years of the most recent articles including tables. Updated annually

■ **More search options** — Search by keyword or phrase, author and/or title using powerful BRS search software

■ **Easier to use** — Find a MEDLINE citation and immediately link to the article, plain-language prompts, tutorial, free technical support

■ **Available now** — All paid orders shipped within 48 hours

Operates on standard IBM PC 286 or 386 and compatibles with a CD-ROM drive. Call for special savings on CD-ROM hardware.

Build a compact library with other medical CD-ROMs from Maxwell Electronic Publishing: *The Lancet, New England Journal of Medicine, Annals of Internal Medicine, Morbidity and Mortality Weekly Reports, Journal of the American Medical Association,* AIDS, Viral Hepatitis.

SPECIAL CHARTER OFFER
20% OFF REGULAR SUBSCRIPTION RATE

☐ **Yes!** Send me Maxwell's BMJ CD-ROM at 20% off the regular price.

☐ **Personal use £217 ea.** (US$315) *(regularly US$395)* ☐ **Institutional use US$440.** *(regularly US$550)*

☐ **Payment enclosed** ☐ **Bill my** ☐ VISA ☐ MC ☐ AMEX

Pounds sterling billable on credit cards for personal use only. Please make checks payable in U.S.$.

Card # _____

Signature _____ Exp. Date ____/____

☐ **Please send additional information on Maxwell Compact Libraries.**
☐ **Please send information on CD-ROM hardware.**

Name _____

Institution _____

Address _____

Country _____

Phone number _____

Facsimile number _____

A0601

Mail to: Maxwell Electronic Publishing
124 Mount Auburn Street
Cambridge, MA 02138 USA

MAXWELL COMPACT LIBRARIES

For immediate delivery,
Fax: 010-617-868-7738
Phone: 010-617-661-2955

gastric distress & oesophagitis

hyperacidity or dysmotility?

Most complaints of gastric distress, as well as oesophagitis, are conventionally attributed to hyperacidity in the stomach. However, the contemporary view in gastroenterology holds that most upper G.I. problems, including heartburn, postprandial fullness, early satiety, abdominal distension and epigastric discomfort, are commonly motility related.[1-3] And this stands to reason. After all, proper peristalsis is a physiological necessity for our digestive process.

Prepulsid, the novel G.I. prokinetic, uniquely restores healthy peristalsis to efficiently clear the oesophagus and empty the stomach.[4-6]



TRADEMARK
Prepulsid
CISAPRIDE

restores upper G.I. motility like no other agent.

JANSSEN
PHARMACEUTICA
B-2340 Beerse, Belgium

expertise in digestive motility

© J Ph. 1991 References: 1. Knuff, J.E., et al.: Dig. Dis. Sci. 29, 194 (1984); 2. Kahrilas, J.P., et al.: Gastroenterology 91, 897 (1986); 3. Malagelada, J.R., et al.: Gastroenterol. 88, 1223 (1985); 4. Ceccatelli, P., et al.: Gut 29, 631 (1988); 5. Collins, B.J., et al.: Hepato-Gastroenterol. 34, 113 (1987); 6. Jian, R., et al.: Dig. Dis. Sci. 34, 657 (1989).

Prescribing information - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. **Therapeutic indications**: 1. Gastroparesis. 2. Symptoms of X-ray or endoscopy negative upper digestive discomfort. 3. Gastro-oesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. **Contra-indications**: No absolute contra-indications are known. **Precautions**: *Pregnancy*: Although in animals, there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. *Nursing mothers*: Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. *Driving and machine-operating ability*: Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. **Interactions**: The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs; absorption of drugs from the stomach may be diminished whereas absorption of drugs from the small bowel may be accelerated (e.g. benzodiazepines, anticoagulants, paracetamol, H_2-blockers). In patients receiving anticoagulants, the coagulation times may somewhat increase. It is advisable to check the coagulation time one week after the start of Prepulsid treatment to adapt the anticoagulant dose if necessary. The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonized by anticholinergic drugs; in hepatic and renal insufficiency, it is recommended to halve the initial daily dose. Drugs when Prepulsid is associated. **Adverse reactions**: In the therapeutic effects or possible side-effects: In the elderly, steady-state plasma levels are generally higher due to a moderate prolongation of the elimination half-life. Therapeutic doses, however, are similar to those used in younger patients; in the case of drugs that require individual titration, it may be useful to monitor plasma levels or suitable pharmacological activity. Prepulsid is associated with the pharmacological activity of Prepulsid: transient abdominal cramping, borborygmi and diarrhoea may occur. Mild and transient headache or lightheadedness have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. There have been isolated reports of convulsive seizures without clear relationship to Prepulsid. **Dosage**: Adults, according to the severity of the condition: 5 or 10 mg of Prepulsid, 2 to 4 times daily, to be taken as tablets or as oral suspension (the full plastic 5 ml spoon contains 5 mg). As a rule the following doses have proven adequate: • less severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. (dose can be doubled); • severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. to 10 mg q.i.d. (before the 3 main meals and before retiring); - infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension intakes are indicated on the dosing pipet as a function of body weight.

Note: Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.

Full prescribing information available on request.